ABSTRACT
ÖZ

Amaç: Tiroid hormonlarının lipid ve glukoz metabolizması üze-rinde etkileri olduğundan, tiroid disfonksiyonu kardiyovasküler hastalıklar için bir risk faktörüdür. Metabolik sendrom (MS) artmış kardiyovasküler hastalık ve tip 2 diyabetes mellitus riski ile birlikte artmış tüm nedenlere bağlı ölümle ilişkilidir. Çalışmalar tiroid disfonksiyonunun artmış MS prevalansı ile ilişkili olduğunu göstermiştir. Bunun yanında, MS'lu hastalarda daha fazla hipotiroidi görülmektedir. Bu çalışmada, levotiroksin tedavisi altındaki hastaların hala daha yüksek metabolik sendrom prevalansına sahip olup olmadıklarını araştırdık.
Method: Çalışmaya levotiroksin tedavisi altında olan hipotiroid
The association between hypothyroidism and MS has become a popular topic of discussion in recent years. Studies have demonstrated that thyroid dysfunction is related to an increased prevalence of MS 7, 8 . Additionally, some studies showed patients with MS had a higher prevalence of hypothyroidism 9, 10 . Lee et al. 11 have demonstrated a higher prevalence of MS in patients with high-normal TSH levels. We aimed to investigate whether hypothyroid patients being treated with levothyroxine still have an increased prevalence of MS or not.
MATERIAL and METHODS
Participants
One hundred and eighty-six hypothyroid patients using levothyroxine were enrolled in the study. Local ethics committee approval was obtained and all participants were provided with written informed consent forms. Fourteen patients diagnosed with thyroid cancer, and sixty patients who were not euthyroid were excluded from the study. Finally, one hundred and eighty-six hypothyroid patients under levothyroxine treatment, in whom euthyroidism was achieved, were enrolled in the study. All individuals were older than 18 years. Patients with pregnancy, heart failure, renal failure, liver failure, infectious disease, rheumatologic disease were also excluded from the study.
Euthyroidism was described as a condition with normal TSH (reference range: 0.35-4.94 uIU/L) and free T4 (reference range: 0.7-1.48 ng/dL) levels. TSH and free T4 levels were measured using a chemiluminescent immunoassay method.
Blood pressures (BP) were measured from both arms with the patient in a sitting position following a minimum of 10 minutes of rest with a suitable mercurial blood pressure monitors. Body weight, waist circumference (WC), height, and body mass index (BMI) were measured by the same person using standard measurement tools.
International Diabetes Federation (IDF) criteria were used for the diagnosis of MS. Diagnosis of MS was made in consideration of the following criteria: waist circumference >94 cm for males or >80 cm for females plus the presence of at least two of the below criteria: BP ≥130/85 mmHg (or current treatment with antihypertensive drug); fasting blood glucose ≥100 mg/ dL (or current treatment with hypoglycemic drug); fasting triglyceride (≥150 mg/ dL or current treatment for elevated triglyceride; high-density lipoprotein cholesterol <40 mg/dL (for males) or <50 mg/dL (for females) or current treatment for reduced HDL-C 12 .
Statistical analysis
All statistical analyses were performed using the JMP 13.0.1 software (SAS Institute, Cary, NC, USA). Mean ± standard deviation was used for expression of quantitative data and numerical values and proportions were used for expression of categorical data. Normality of distribution was examined by using the pressure levels (p<.01) were significantly higher in patients with MS when compared to those patients without MS while HDL cholesterol levels were significantly lower (p<.0001) ( Table 2) .
Mean age, BMI, systolic and diastolic BP, WC, triglyceride, fasting plasma glucose, Hba1c, HOMA-IR, creatinine, and GGT levels were higher in patients with MS when compared to those of the patients without MS. HDL cholesterol levels were lower in patients with MS ( Table 2) . Table 3) .
DISCUSSION
In our study, MS was seen in 52% of hypothyroid patients using levothyroxine. The frequency of MS was higher among hypothyroid patients treated with levothyroxine relative to general population. These results suggest that metabolic syndrome was more frequently seen even among treated hypothyroid patients.
Thyroid hormones modulate basal metabolism, thermogenesis and have a significant role in lipid and glucose metabolism, food intake and oxidation of fatty acids 13 . Hypothyroidism leads to mild hypertension due to low cardiac output, a decrease in ventricular filling, and cardiac contractility and an increase in systemic vascular resistance 14 . Thyroid hormones have an impact on the synthesis, metabolism, and mobilization of lipids by regulating the activities of key enzymes in lipoprotein metabolism 15 . Hypothyroidism may lead to accelerated atherosclerosis and coronary heart disease, probably as a result of hypercholesterolemia and hypertension 14 . Increased TSH concentrations are related to increased body weight 16 .
Even small variations in TSH could result in an increase in body weight 17 . Hypothyroidism is considered to be a risk factor for insulin resistance. Hypothyroidism leads to a decrease in the rate of intestinal glucose absorption, a decrease in liver and muscle glycogenolysis by lowering the adrenergic activity and a reduction in gluconeogenesis and basal insulin secretion. Nevertheless, insulin secretion and free fatty acids levels increase postprandially with a decreased glucose uptake and increased glucose oxidation 18 . Handisurya et al. 19 showed that levothyroxine treatment improved insulin tolerance in hypothyroid patients.
Hypothyroidism has negative effects on total cholesterol, LDL, Apo AI, Apo B, and lipoprotein (a) levels [20] [21] [22] . Caron et al. 23 reported that hypothyroidism was associated with lower HDL-C levels that increased with levothyroxine treatment.
Thyroid hormones have an adverse effect on all parameters of MS including lipid and glucose metabolism, BP and weight; hence thyroid dysfunction may lead to the onset of MS 24 . Shantha et al. 25 reported that hypothyroidism was re- Various studies have evaluated the impact of levothyroxine treatment on metabolic parameters. Bakiner et al. 27 could not find any decrease in body weight and body fat percentage with levothyroxine treatment. Efstathiadou et al. 20 notified that patients with subclinical hypothyroidism have elevated concentrations of the atherogenic lipids (mainly LDL-C and Lp(a)), however, levothyroxine treatment did not improve dyslipidemia in these patients. In a study conducted in hypercholesterolemic patients, the liver-selective thyromimetic eprotirome was shown to decrease serum levels of atherogenic lipoproteins 28 . BMI, WC, BP, triglyceride, fasting plasma glucose, Hba1c, HOMA-IR levels were higher and HDL cholesterol levels were lower in our patients with MS as expected 4 . Hu W et al. 29 showed that MS was independently related to a mildly reduced glomerular filtration rate. We found higher creatinine concentrations in patients with MS. Elevated serum GGT level predicts the onset of MS. We found higher GGT levels in patients with MS.
MS is described as a pandemic affecting 20 to 30% of adult population worldwide 30 , while 9.2 million adult people aged ≥ 30 years and 53% of the patients with coronary artery disease suffered from MS according to TEKHARF study conducted in 2000 31 . METSAR (Tür-kiye Metabolik Sendrom Araştırması) study reported the prevalence of MS as 33.9% among adults in Turkey 32 . Gundogan et al. 6 reported the prevalence of MS in Turkey as 44% according to IDF criteria. According to data of PURE (Prospective Urban Epidemiological Study) Turkey study conducted with 4057 adults; the prevalence rates of MS in women and men were 43.5% and 41.4% respectively. Additionally, the prevalence of MS increases as the population ages. As a matter of fact the prevalence of MS in adults 60-64 years old was 57.7% 33 . We aimed to investigate whether hypothyroid patients under levothyroxine treatment still have a higher prevalence of MS or not. We evaluated the prevalence and parameters of MS in these euthyroid patients. We found that the prevalence of MS is 52% in these patients. These results may show that the prevalence of MS is still high in hypothyroid patients even if they are using levothyroxine treatment. Therefore, MS should be considered in these patients even they are euthyroid. The prevalence of MS found in our study was higher than the results of these mentioned studies conducted in Turkey. These findings could be explained by slightly older patients included in our study.
A cross-sectional design, being a single-center trial, relatively small sample size are limitations of our study.
In conclusion, the prevalence of metabolic syndrome is still high in hypothyroid patients under levothyroxine treatment. Moreover, more comprehensive studies should be performed in a larger population to enlighten this association.
